Sikkim Journal

Dravet Syndrome Emerging drugs and Key Players | DelveInsight

 Breaking News
  • No posts were found

Dravet Syndrome Emerging drugs and Key Players | DelveInsight

August 01
09:20 2020
Dravet Syndrome Emerging drugs and Key Players | DelveInsight

DelveInsight Business Research LLP
Dravet Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dravet Syndrome market. A detailed picture of the Dravet Syndrome pipeline landscape is provided, which includes the disease overview and Dravet Syndrome treatment guidelines.

Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.


Dravet Syndrome Emerging drugs 

Dravet Syndrome Emerging Drugs

  1. ZX008 by Zogenix
  2. Soticlestat by Ovid Therapeutics
  3. Ataluren by PTC Therapeutics

Dravet Syndrome Marketed Drugs

  1. Diacomit by Biocodex
  2. Epidiolex by GW Pharmaceuticals


Companies have shifted their focus on the development of second-generation therapeutics that follow the step of the most advanced cannabidiol formulation (Epidiolex) and the most advanced serotonergic drug (Fintepla). Most of these compounds would have the potential to treat other forms of epilepsy and are expected to hit Dravet Syndrome market during the forecast period of 2020–2030. 


Request for sample pages

Table of contents

1. Report Introduction

2. Dravet Syndrome 

2.1. Overview

2.2. History 

2.3. Dravet Syndrome Symptoms

2.4. Causes


2.6. Dravet Syndrome Diagnosis 

2.6.1. Diagnostic Guidelines

3. Dravet Syndrome Current Treatment Patterns

3.1. Dravet Syndrome Treatment Guidelines

4. Dravet Syndrome – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Dravet Syndrome companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Dravet Syndrome Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Dravet Syndrome Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Dravet Syndrome Late Stage Products (Phase-III)

7. Dravet Syndrome Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dravet Syndrome Discontinued Products

13. Dravet Syndrome Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

14. Dravet Syndrome Key Companies

15. Dravet Syndrome Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Dravet Syndrome Unmet Needs

18. Dravet Syndrome Future Perspectives

19. Dravet Syndrome Analyst Review  

20. Appendix

21. Report Methodology

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States

Related Articles